News from amgen A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 20, 2023, 16:00 ET AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS

Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen's oncology research and...

Sep 11, 2023, 16:00 ET AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday, Sept. 14, 2023....

Sep 10, 2023, 09:00 ET AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS®...

Sep 07, 2023, 16:00 ET AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m. ET on Tuesday, Sept. 12, 2023. Robert A. Bradway,...

Sep 01, 2023, 09:20 ET AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade...

Aug 31, 2023, 19:30 ET AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will also present...

Aug 26, 2023, 10:45 ET AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023

Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA)...

Aug 21, 2023, 16:00 ET AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting ...

Aug 03, 2023, 16:01 ET AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023. "We had a very strong quarter, serving more patients across all ...

Aug 01, 2023, 16:00 ET AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will...

Jul 31, 2023, 16:00 ET AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. ...

Jul 31, 2023, 08:04 ET AMGEN AMPLIA O NÚMERO DE MULHERES NA LIDERANÇA

A Amgen anuncia promoções internas que reforçam o compromisso e o objetivo de identificar o potencial dos colaboradores, desenvolver os profissionais ...

Jul 24, 2023, 07:51 ET AMGEN AMPLIA O NÚMERO DE MULHERES NA LIDERANÇA

A Amgen anuncia promoções internas que reforçam o compromisso e o objetivo da marca de identificar o potencial dos colaboradores, desenvolver os...

Jun 21, 2023, 09:00 ET FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...

Jun 09, 2023, 16:00 ET AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023. Robert A. ...

Jun 04, 2023, 08:00 ET AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development ...

Jun 01, 2023, 09:00 ET AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

New LUMAKRAS® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS...

May 30, 2023, 18:00 ET AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study ...

May 26, 2023, 16:00 ET AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT

Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese,...

May 24, 2023, 08:18 ET MAIO ROXO ALERTA PARA AS DOENÇAS INFLAMATÓRIAS INTESTINAIS (DII) E CÂNCER COLORRETAL

De acordo com a Sociedade Brasileira de Coloproctologia (SBCP), as doenças inflamatórias intestinais (DII) são caracterizadas pela inflamação de...

May 16, 2023, 11:31 ET AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS

Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the...

May 09, 2023, 09:00 ET AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target...

May 08, 2023, 09:00 ET NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S....

May 03, 2023, 16:00 ET AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 9, 2023....

Apr 27, 2023, 16:01 ET AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023. "We delivered 14% volume growth driven by the breadth of our...